Brainsway’s Strong Q4 Performance and Strategic Growth Drive Buy Rating with $16 Price Target

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Brainsway (BWAY – Research Report). The associated price target remains the same with $16.00.

Ram Selvaraju has given his Buy rating due to a combination of factors including Brainsway’s strong financial performance in the fourth quarter of 2024, where the company exceeded both revenue and earnings expectations. The company reported $11.4 million in revenue, surpassing the forecast of $10.7 million, and achieved net earnings of $0.09 per share, higher than the anticipated $0.07 per share. This positive performance has led to an optimistic outlook for 2025, with revenue projections increased to $50.8 million, reflecting management’s confidence and financial guidance.
Additionally, Brainsway’s strategic flexibility is bolstered by nearly $70 million in cash and equivalents, which could facilitate potential technology licensing deals to expand its product offerings. The company is also making significant progress in clinical trials and expanding its market presence, including FDA labeling expansions and international market penetration. These developments, along with the continued growth in Deep TMS system installations and collaborations with mental health networks, support the Buy rating and the 12-month price target of $16 per share.